<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 393 from Anon (session_user_id: ed3a138576dbfc880078b0efd64ca12ded3318d8)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 393 from Anon (session_user_id: ed3a138576dbfc880078b0efd64ca12ded3318d8)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p><span>In normal cell CpG islands tends to be protected from methylation and DNA methylation in CpG  islands is silencing of gene expression, eg. some oncogenes. In cancer cell  CpG islands and CpG islands shores of tumour suppressor genes is hypermethylation so those genes-controlling cell cycle, apoptosis or DNA repair are silencing which cause the tumour worse . In normal cell intergenic regions and repetitive elements usually methylated which can maintain genomic integrity and genome defense model. In cancer cell  intergenic regions and repetitive elements are  hypomethylation. Those cells cause the tumour worse with the genomic instability.</span></p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p><span>In paternal allele DNA methylation at ICR  blocks the binding of CTCF which is an insulator protein,insulates Igf2 from downstream enhancers. Without CTCF, DNA methylation speards to H19 promoter to silence and enhancers can access Igf2 to activate. In maternal allele ICR is unmethylated so CTCF can binding on it to stop the activation of downstream enhancers  to  Igf2 expression. H19 is unmethylated and downstream enhancers can work on it, so it can express. In Wilm’s tumour both alleles are methylated as normal paternal allele so the expression of  Igf2 is double. Igf2 can stimulate normal cellular growth, changes to IGF2 regulation and expression can produce deleterious physiological consequences. Nearly every gene that is imprinted has been implicated as a regulator of embryonic, chorionic, or adult growth or metabolism; IGF2 is a factor that is involved at all three stages. (Loss of imprinting)LOI of the IGF2 gene has been clearly demonstrated to have a strong association with the development of several forms of cancer.The precise mechanism of LOI mediated tumorigenesis remains elusive.</span></p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p><span>It is DNA-demethylating agent. It hypomethylates DNA by inhibiting DNA methyltransferase.  If it is an increase in DNA methylation this can result in the blockage of the activity of "suppressor genes" that regulate cell division and growth.  When suppressor genes are blocked, cell division becomes unregulated, allowing or promoting cancer. Decitabine works is by demethylation or interfering with the methylation of DNA.  By this process of demethylation, normal function to the tumor suppressor genes is restored, thus restoring control over cell growth.</span></p></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><p><span>Decitabine is DNA-demethylating agent. It hypomethylates DNA by inhibiting DNA methyltransferase.  When there is an increase in DNA methylation this can result in the blockage of the activity of "suppressor genes" that regulate cell division and growth.  When suppressor genes are blocked, cell division becomes unregulated, allowing or promoting cancer. Decitabine works is by demethylation or interfering with the methylation of DNA.  By this process of demethylation, normal function to the tumor suppressor genes is restored, thus restoring control over cell growth.</span></p></div>
  </body>
</html>